Boston Scientific Corp. priced a public offering of $1 billion of its 4.000% senior notes due March 1, 2028.
The company plans to use the net proceeds to redeem its 2.650% notes due October 2018, and to repay short-term debt and pay related fees, expenses and premiums.
Boston Scientific expects to receive the net offering proceeds upon closing Feb. 26, subject to customary closing conditions.
